Objective measurement and clinical significance of TILs in non-small cell lung cancer

Journal of the National Cancer Institute

Volumn 107, Issue 3, 2015, Pages

  Schalper, Kurt A ^a   Brown, Jason ^a   Carvajal Hausdorf, Daniel ^a   McLaughlin, Joseph ^a   Velcheti, Vamsidhar ^b   Syrigos, Konstantinos N ^c   Herbst, Roy S ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CD20 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; CYTOKERATIN; FLUORESCENT DYE; INDOLE DERIVATIVE;

AGE; AGED; ARTICLE; CANCER CELL; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FLUORESCENCE ANALYSIS; HISTOLOGY; HISTORY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; SMOKING; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC USE; EPIDEMIOLOGY; FLUORESCENCE MICROSCOPY; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG TUMOR; MORTALITY; PREDICTIVE VALUE; RETROSPECTIVE STUDY;

ANTIGENS, CD20; ANTIGENS, CD3; ANTIGENS, CD8; CARCINOMA, NON-SMALL-CELL LUNG; CONFOUNDING FACTORS (EPIDEMIOLOGY); FLUORESCENT DYES; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MICROSCOPY, FLUORESCENCE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84927173508     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju435     Document Type: Article

References (22)

1. Fridman WH, Pagès F, Sautès-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298-306.
2. Horne ZD, Jack R, Gray ZT, et al. Increased levels of tumorinfiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res. 2011;171(1):1-5.
3. Kilic A, Landreneau RJ, Luketich JD, et al. Density of tumorinfiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J Surg Res. 2011;167(2):207-210.
4. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94(1):107-116.
5. Zhuang X, Xia X, Wang C, et al. A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol. 2010;18(1):24-28.
6. Mori M, Ohtani H, Naito Y, et al. Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. Tohoku J Exp Med. 2000;191(2):113-118.
7. Wakabayashi O, Yamazaki K, Oizumi S, et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. 2003;94(11):1003-1009.
8. Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006;94(2):275-280.
9. Gu-Trantien C, Loi S, Garaud S, et al. CD4? follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123(7):2873-2892.
10. Di Caro G, Bergomas F, Grizzi F, et al. Occurrence of tertiary lymphoid tissue is associated to T cell infiltration and predicts better prognosis in early stage colorectal cancers. Clin Cancer Res. 2014; In press.
11. Brahmer JR. Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol. 2013;31(8):1021-1028.
12. Hamid O, Schmidt H, Nissan A, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204.
13. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
14. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res. 2013;19(5):1021-1034.
15. Anagnostou VK, Syrigos KN, Bepler G, et al. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol. 2009;27(2):271-278.
16. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8(11):1323-1327.
17. Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2014;20(23):5995-6005.
18. Schalper KA, Velcheti V, Carvajal D, et al. In situ Tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20(10):2773-2782.
19. Galon J, Pagès F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012;10:205.
20. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014;232(2):199-209.
21. Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008;14(16):5220-5227.
22. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-571.